

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2016/141215 A1

(43) International Publication Date

9 September 2016 (09.09.2016)

WIPO | PCT

(51) International Patent Classification:

A61F 2/90 (2013.01) A61F 2/958 (2013.01)

(21) International Application Number:

PCT/US2016/020743

(22) International Filing Date:

3 March 2016 (03.03.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/127,370 3 March 2015 (03.03.2015) US

(71) Applicant: EFEMORAL MEDICAL LLC [US/US];  
2300 Deodara Drive, Los Altos, California 94024 (US).

(72) Inventors; and

(71) Applicants : SCHWARTZ, Lewis B. [US/US]; 570  
Hathaway Circle, Lake Forest, Illinois 60045 (US). ORR,  
Gregory [US/US]; 27940 Turner Heights Lane, Escon-  
dido, California 92026 (US). SANTOS, Jayson Delos  
[US/US]; 42 Silk Oak Terrace, Fremont, California 94536  
(US). HAIG, Christopher [US/US]; 2300 Deodara Drive,  
Los Altos, California 94024 (US).

(74) Agent: GARFINKEL, Jonathan; Convergence Intellectual Property Law P.C., 2251 Grant Road, Suite G, Los Altos, California 94024 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: MULTI-ELEMENT BIORESORBABLE INTRAVASCULAR STENT



(57) Abstract: A multi-element, bioresorbable, vascular stent may be used to maintain or enhance patency of a blood vessel. The stent may be used in peripheral blood vessels, which may be long and/or tortuous. By using multiple, separate stent elements that are balloon expandable, the multi- element stent may be stronger than a traditional self-expanding stent but may also be more flexible, due to its multiple-element configuration, than a traditional balloon-expandable stent. Thus, the multi-element, bioresorbable, vascular stent described herein may be particularly advantageous for treating long lesions in tortuous peripheral blood vessels.

WO 2016/141215 A1

**MULTI-ELEMENT BIORESORBABLE INTRAVASCULAR STENT****CROSS-REFERENCES TO RELATED APPLICATIONS**

**[0001]** This application claims the benefit and priority of U.S. Provisional Patent Application No. 62/127370, entitled “MULTI-ELEMENT BIORESORBABLE INTRAVASCULAR STENT”, filed on March 3, 2015, the full disclosure of the above referenced application is incorporated herein by reference.

**FIELD OF THE INVENTION**

**[0002]** The present application pertains generally to the field of medical devices. More specifically, the present application pertains to bioresorbable vascular stents for tortuous vessels.

**BACKGROUND**

**[0003]** Atherosclerotic cardiovascular disease is the leading cause of death and disability in the world, accounting for nearly one-third of all human mortality. Over the past fifty years, significant progress has been made in the understanding and primary prevention of atherosclerosis. Still, as patients age and their arteries become brittle and elongated, early atherosclerotic plaques inexorably progress to their occlusive end-stage and induce the clinical syndromes of angina pectoris (chest pain), transient ischemic attack (reduced blood flow to the heart) and claudication (leg pain due to poor circulation) and their sinister end-stages of myocardial infarction (“heart attack”), stroke and amputation.

**[0004]** In the modern era, the mainstay of therapy for established vascular lesions is percutaneous balloon angioplasty (dilating the constricted artery with a balloon catheter) and stent implantation. The procedure is widely used, over 2,000,000 procedures performed annually, and the short-term results are favorable in >95% of patients. Significant problems with angioplasty and stenting remain, however, including the requirement for continued antiplatelet medication as the artery heals, the frequent need for early re-intervention for restenosis (when the stented artery closes down again), and thrombosis (clot formation). Furthermore, although there has been remarkable progress in intravascular stent development, stents still generate an alarming number of long-term complications, including fracture and late thrombosis.

**[0005]** In order to circumvent the myriad problems associated with permanent metal implants, stents that slowly dissolve after deployment have long been imagined and researched. Due to their temporary nature, such devices are also known as “scaffolds” rather than “stents” which remain in the body permanently. Bioresorbable vascular scaffolds (BVS or “bioresorbable stents”) potentially offer several key biologic and physiologic advantages, including: (1) effective scaffolding without the permanence of a metal implant; (2) attenuation of chronic inflammation and foreign body reaction; (3) promotion of adaptive vascular remodeling; (4) restoration of physiologic vasoactive function; and (5) facilitation of imaging and surveillance during follow-up. Despite their promise, however, the devices have proven challenging to successfully design, develop and manufacture. At the current time, only two coronary devices and a single peripheral device are available commercially in Europe, and no devices have yet been approved for use in the United States.

**[0006]** A key limitation of intravascular stents is their inability to conform to and accommodate the natural bending and twisting of blood vessels during human movement. This is particularly problematic in the blood vessels of the extremities, which bend and twist in unpredictable fashion, depending on the type, degree and rapidity of human motion. For instance, Cheng et al. quantified in vivo arterial deformation using magnetic resonance

angiography and found that, during movement from the supine to the fetal position, the superficial femoral artery (SFA) shortened an average of 13% and twisted an average of 60°. A subsequent study in elderly subjects found lesser degrees of shortening with flexion, but substantially more curvature and buckling. Other studies have had similarly dramatic results.

**[0007]** The motion and deformation of stents implanted in actual human SFAs has also been studied. For instance, Nikanorov et al. deployed eleven 100 mm self-expanding nitinol stents in the femoropopliteal arteries of eight cadavers and assessed length and deflection via lateral view radiographs obtained during simulated flexion. The results showed that stents implanted in the SFA and popliteal arteries exhibited compression of up to 10.7%, depending on the degree of flexion. More notably, stents implanted in the mid-popliteal artery bent an average of 54° when the leg was fully flexed.

**[0008]** Stents implanted in short, motionless arteries are typically rigid and non-deformable. So-called “balloon-expandable” stents are deployed by inflating their delivery balloon within the target lesion and embedding the rigid scaffold within the vessel wall. The final stent shape is fixed, casted and restrained by the contour of its surrounding vessel. Its architecture is permanent; reimaging the device over time generally reveals no change in the diameter that was achieved during the procedure.

**[0009]** In contrast, the length and motion of the long extremity vessels mandates that stents designed for this anatomic location have the properties of flexibility and conformability. Most devices designed for the extremities are made of a nickel-titanium alloy known as “Nitinol” which has intrinsic properties of super-elasticity and shape memory. Nitinol stents are “self-expanding”, they are deployed by progressively releasing the device from a long tube in which it is housed. The delivery system does not contain a balloon (although the device is routinely “post-dilated” with a balloon that is separately inserted). Unlike balloon-expandable stents, self-expanding Nitinol stents are neither rigid nor fixed. Their flexibility allows them to recover

when deformed, a critical property for a long device implanted into an extremity artery. In this respect, Nitinol stents resemble bypass grafts: flexible, long conduits that carry blood past obstructive lesions.

**[0010]** However, the necessity for flexibility and conformability in peripheral vascular stents means that these stents have historically had far less radial strength than typical balloon expandable stents. In this regard, such flexible, conformable stents do little to actually “stent” (or “prop open”) the artery; unconstrained by a scaffold, the artery is free to collapse over time. Furthermore, stents designed in this manner must be “oversized,” to remain in place and continue to exert a “chronic outward force” upon the vessel until such time that the nominal diameter of the device is reached. Some have theorized that the chronic force imparts continuous injury to the artery, resulting in poor long-term patency. Thus, the design of an effective, self-expanding, flexible stent is fundamentally different from traditional, rigid, “balloon-expandable” metal stents, which exert a singular “stretch” at the time of implantation and then remain inert as the vessel recovers and remodels.

**[0011]** The length and persistent motion of the extremity arteries also lead to a tendency toward fracture of stents implanted in those arteries. Stent fracture following femoropopliteal implantation is alarmingly common. Movement of the legs is a complex motion; loading of the hips and knees during ambulation repeatedly compresses the arteries axially and can even produce multidimensional bends, twists and kinks. This results in single or multiple strut fractures or, in severe cases, complete stent transection. Fracture is more common after implantation of long and/or overlapping stents and, possibly, in more active patients. Fracture of intravascular stents is clearly associated with restenosis.

**[0012]** Therefore, it would be advantageous to have a bioresorbable stent for use in peripheral vasculature that is easier to design, develop and manufacture than currently available stents. Ideally, such a stent would have a desirable flexibility and conformability profile while

also having sufficient strength to withstand the stresses placed on peripheral vascular stents, as described above. This would make the stent more useful and effective, and safe for the treatment of long, tortuous blood vessels. Ideally, such a stent would also provide at least some of the advantages of absorbable (or “bioresorbable”) stents listed above. At least some of these objectives will be met by the embodiments described below.

## SUMMARY

**[0013]** The embodiments herein describe an apparatus for maintaining the luminal integrity of long, naturally moveable and flexible human blood vessels by simultaneous deployment of multiple independent, repeating, rigid scaffold units. The embodiments may include multiple, rigid, repeating units that are closely spaced within the vessel but do not touch one another, even when skeletal movement or myocardial contraction causes the vessel to move.

**[0014]** In some embodiments, a stent may include multiple, rigid, potentially articulating elements, which are simultaneously implanted along the length of a vessel via balloon inflation. Each element of the stent may have relatively high radial force (rigidity), similar or greater in magnitude to that of traditional, balloon-expandable stents. Each element may also be relatively short and rigid, so that its nominal diameter will be reached immediately upon balloon inflation, and thus it will not exert chronic forces upon the vessel. Additionally, because each element is relatively short in length, each may move independently, in concert with the segment of artery into which it is implanted. In this way, such a stent may be used safely in any vessel of the body, regardless of the vessel's length, proximity to joints or range of motion. Finally, in some embodiments, all the elements of the stent may be morphologically identical, so that their fabrication may be simpler than that used for currently available stents.

**[0015]** In one aspect, a method of making a multi-element, bioresorbable, vascular stent may involve forming a length of the bioresorbable, vascular stent from a bioresorbable material that is balloon expandable and not self-expanding and cutting the length of the bioresorbable, vascular stent to form multiple stent elements of the stent. In some embodiments, forming the length of the bioresorbable, vascular stent comprises using an additive manufacturing process. For example, the additive manufacturing process may be micro-stereolithography. In some embodiments, the additive manufacturing process may be 3D printing. In various embodiments, the bioresorbable material may be poly(L-lactic acid) (PLLA), polyglycolic acid (PGA), or

poly(iodinated desaminotyrosyl-tyrosine ethyl ester) carbonate. Some embodiments may further involve applying a coating to the bioresorbable material. In some embodiments, the coating may be poly-D,L-lactide (PDLLA). Optionally, the method may further involve applying a drug to the stent. For example, the drug may be everolimus or any other anti-proliferative drug, in various embodiments.

**[0016]** In another aspect, a device for placement within a blood vessel to maintain or enhance blood flow through the blood vessel may include multiple, balloon-expandable, bioresorbable, vascular stent elements configured to be implanted in the blood vessel as a multi-element stent, with the multiple stent elements not touching one another. In some embodiments, the stent elements are fabricated by an additive manufacturing process.

**[0017]** In some embodiments, stent elements comprise a first set of closed cells and a second set of closed cells, wherein the first set of closed cells have a different shape or size than the second set of closed cells. The first set of closed cells may have a repeating longitudinally aligned pattern and a repeating circumferentially aligned pattern. The second set of closed cells may also have a repeating longitudinally aligned pattern and a repeating circumferentially aligned pattern. The first set of closed cells and the second set of closed cells may be circumferentially offset and have a helically aligned alternating pattern.

**[0018]** In an embodiment, the first set of closed cells are larger cells having a first opening dimension and the second set of closed cells are smaller cells having a second opening dimension smaller than the first opening dimension. Each of the larger closed cells may be formed by at least one wider strut between adjacent longitudinally aligned larger closed cells and at least one thinner strut between adjacent circumferentially aligned larger closed cells. Larger closed cells may also be formed by at least one intermediate-width strut, wherein the intermediate-width strut between adjacent helically aligned larger closed cells and smaller closed cells.

**[0019]** In another embodiment, the first set of closed cells have a first lobular shape and the second set of closed cells have a second lobular shape. The first set of closed cells may comprise longitudinally aligned lobes and circumferentially aligned lobes. Longitudinally aligned lobes may be larger than the circumferentially aligned lobes. Adjacent longitudinally aligned lobes may be connected by longitudinal connecting struts and adjacent circumferentially aligned lobes may be connected by circumferential connecting struts.

**[0020]** In an embodiment, the first set of closed cells are ratcheting cells comprising a longitudinally aligned ratcheting strut. Teeth on a portion of the ratcheting strut may be configured to move within a cavity while expanding the element and engage a pawl.

**[0021]** In an embodiment, the first set of closed cells are bistable cells comprising a circumferentially aligned bistable strut having a bistable spring band configuration. The bistable struts may have a concavo-convex shape with the concave curve longitudinally oriented.

**[0022]** In an alternative embodiment, the stent elements may have a corrugated cylindrical configuration with alternating convex ridges and concave grooves. Corrugated elements may have solid walls or non-solid walls with cell patterns.

**[0023]** In another embodiment, the stent elements comprise an alternating sequence of two larger cells and a set of smaller cells, wherein the two larger cells are formed by a pivoting strut between the two larger cells. The pivoting strut may be configured to pivot from a less rigid state to a more rigid state.

**[0024]** In another aspect, a method for maintaining or enhancing blood flow through a blood vessel may involve advancing a balloon catheter into the blood vessel, expanding a balloon on the balloon catheter to expand multiple, bioresorbable, vascular stent elements mounted on the balloon to contact an inner wall of the blood vessel, deflating the balloon, while leaving the vascular stent elements in place in the blood vessel, and removing the balloon

catheter from the blood vessel. In some embodiments, the blood vessel may be a peripheral blood vessel. In some embodiments, expanding the stent elements comprises expanding at least four elements. In some embodiments, the elements are separated from one another along the balloon, wherein expanding the elements comprises delivering the elements to the inner wall of the blood vessel in a spaced-apart configuration.

**[0025]** This and other aspects of the present disclosure are described herein.

BRIEF DESCRIPTION OF THE DRAWINGS

**[0026]** Present embodiments have other advantages and features which will be more readily apparent from the following detailed description and the appended claims, when taken in conjunction with the accompanying drawings, in which:

**[0027]** FIGs. 1A-1C are side views of a self-expanding Nitinol stent placed in a distal SFA and popliteal artery, illustrated during different amounts of leg flexion.

**[0028]** FIGs. 2A and 2B are side and magnified views, respectively, of a full-length bioresorbable vascular scaffold, according to one embodiment.

**[0029]** FIGs. 3A and 3B are side and magnified views, respectively, of a bioresorbable vascular scaffold designed with multiple, rigid, independent elements, according to one embodiment.

**[0030]** FIGs. 4A-4D are various views of the bioresorbable vascular scaffold of FIGs. 3A and 3B illustrated in place along a curved tube to illustrate the ability of the stent elements to conform to curves in a blood vessel, according to one embodiment.

**[0031]** FIGs. 5A-5C are side, end-on and magnified views, respectively, of a stent, according to one embodiment.

**[0032]** FIGs. 6A and 6B are side and magnified views, respectively, of a stent, according to an alternative embodiment.

**[0033]** FIG. 7 is a schematic diagram of a micro-stereolithograph used to create a stent, according to one embodiment.

[0034] FIG. 8A is a two-dimensional depiction of an element having a lobular cell structure. FIG. 8B is a magnified view of the cells in FIG. 8A. FIG. 8C shows the stent element of FIG. 8A in cylindrical form.

[0035] FIG. 9A is a two-dimensional depiction of an element having an alternative lobular cell structure. FIG. 9B is a magnified view of a cell in FIG. 9A.

[0036] FIG. 10A is a two-dimensional depiction of an element having a ratcheting configuration. FIG. 10B is a magnified view of the cells in FIG. 10A. FIG. 10C is an isometric view of the cells in FIG. 10A. FIG. 10D is a cross-sectional view of the cells in FIG. 10C showing a ratchet. FIG. 10E is a magnified view of a ratchet in FIG. 10D. FIG. 10F is an alternative view of a ratchet in cross-section.

[0037] FIG. 11A is a two-dimensional depiction of an element having a bistable spring band configuration. FIG. 11B is a magnified view of the cells in FIG. 11A. FIG. 11C is an isometric view of the cells in FIG. 11A. FIG. 11D is a cross-sectional view of the cells in FIG. 11C showing the curvature of bistable strut **1103**. FIG. 11E is a magnified view of a bistable strut **1103** in FIG. 11D. FIG. 11F is an alternative view of a bistable strut **1103** in cross-section.

[0038] FIG. 12A is a two-dimensional depiction of an element having a pivoting configuration. FIG. 12B is a magnified view of the cells in FIG. 12A.

[0039] FIG. 13A is a side view of a cylindrical element having a corrugated or arch configuration. FIG. 13B is a top view of a corrugated element. FIG. 13C is a magnified view of the element in FIG. 13B. FIG. 13D is an isometric view of a cylindrical element having a corrugated configuration. FIG. 13E a magnified view of the element in FIG. 13E.

### DETAILED DESCRIPTION

[0040] While the invention has been disclosed with reference to certain embodiments, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the scope of the invention. In addition, many modifications may be made to adapt to a particular situation or material to the teachings of the invention without departing from its scope.

[0041] Throughout the specification and claims, the following terms take the meanings explicitly associated herein unless the context clearly dictates otherwise. The meaning of “a”, “an”, and “the” include plural references. The meaning of “in” includes “in” and “on.” Referring to the drawings, like numbers indicate like parts throughout the views. Additionally, a reference to the singular includes a reference to the plural unless otherwise stated or inconsistent with the disclosure herein.

[0042] The word “exemplary” is used herein to mean “serving as an example, instance, or illustration.” Any implementation described herein as “exemplary” is not necessarily to be construed as advantageous over other implementations.

[0043] Various embodiments are described herein with reference to the figures. The figures are not drawn to scale and are only intended to facilitate the description of the embodiments. They are not intended as an exhaustive description of the invention or as a limitation on the scope of the invention. In addition, an illustrated embodiment needs not have all the aspects or advantages shown. An aspect or an advantage described in conjunction with a particular embodiment is not necessarily limited to that embodiment and can be practiced in any other embodiments even if not so illustrated.

[0044] FIGs. 1A-1C are side views of a self-expanding, Nitinol stent **200** placed in a distal SFA and popliteal artery A, illustrated during different amounts of leg flexion. FIG. 1A

illustrates stent **200** with the leg in the neutral position, minimal flexion/mostly extended. FIG. 1B illustrates stent **200** during partial flexion, with a circle and bend radius **202** illustrating the angle of flexion and the curved deformation of stent **200**. FIG. 1C illustrates stent **200** during greater flexion. As FIGs. 1A-1C illustrate, stent **200** is markedly deformed by flexion of the leg.

**[0045]** Referring now to FIG. 7, in one embodiment, bioresorbable vascular scaffolds (BVSs) may be manufactured using a micro-stereolithography system **100** (or “3D printing system”). Several examples of currently available systems that might be used in various embodiments include, but are not limited to: MakiBox A6, Makible Limited, Hong Kong; CubeX, 3D Systems, Inc., Circle Rock Hill, SC; and 3D-Bioplotter, (EnvisionTEC GmbH, Gladbeck, Germany).

**[0046]** The micro-stereolithography system may include an illuminator, a dynamic pattern generator, an image-former and a Z-stage. The illuminator may include a light source, a filter, an electric shutter, a collimating lens and a reflecting mirror that projects a uniformly intense light on a digital mirror device (DMD), which generates a dynamic mask. FIG. 7 shows some of these components of one embodiment of the micro-stereolithography system **100**, including a DMD board, Z-stage, lamp, platform, resin vat and an objective lens. The details of 3D printing/micro-stereolithography systems and other additive manufacturing systems will not be described here, since they are well known in the art. However, according to various embodiments, any additive manufacturing system or process, whether currently known or hereafter developed, may potentially be used to fabricate BVSs within the scope of the present invention. In other words, the scope of the invention is not limited to any particular additive manufacturing system or process.

**[0047]** In one embodiment, the system **100** may be configured to fabricate BVSs using dynamic mask projection micro-stereolithography. In one embodiment, the fabrication method may include first producing 3D microstructural scaffolds by slicing a 3D model with a computer

program and solidifying and stacking images layer by layer in the system. In one embodiment, the reflecting mirror of the system is used to project a uniformly intense light on the DMD, which generates a dynamic mask. The dynamic pattern generator creates an image of the sliced section of the fabrication model by producing a black-and-white region similar to the mask. Finally, to stack the images, a resolution Z-stage moves up and down to refresh the resin surface for the next curing. The Z-stage build subsystem, in one embodiment, has a resolution of about 100 nm and includes a platform for attaching a substrate, a vat for containing the polymer liquid solution, and a hot plate for controlling the temperature of the solution. The Z-stage makes a new solution surface with the desired layer thickness by moving downward deeply, moving upward to the predetermined position, and then waiting for a certain time for the solution to be evenly distributed.

**[0048]** In any of the described embodiments, stents or stent elements may be manufactured as a sheet and wrapped into cylindrical form. Alternatively, stents or stent elements may be manufactured in cylindrical form using an additive manufacturing process.

**[0049]** In an embodiment shown in FIGs. 6A-6B, stents or stent elements may be fabricated using non-bioresorbable material, including 1,6-hexanediol diacrylate with 2% DMPA as a photoinitiator, and 0.10% Tinuvin 327 as a light absorber. In various alternative embodiments, the stent or stent element may be made from any suitable bioresorbable material, such as but not limited to poly(L-lactic acid) (PLLA), polyglycolic acid (PGA), poly(iodinated desaminotyrosyl-tyrosine ethyl ester) carbonate, or the like.

**[0050]** In alternative embodiments, any suitable polymer may be used to construct the stent. The term “polymer” is intended to include a product of a polymerization reaction inclusive of homopolymers, copolymers, terpolymers, etc., whether natural or synthetic, including random, alternating, block, graft, branched, cross-linked, blends, compositions of blends and variations thereof. The polymer may be in true solution, saturated, or suspended as particles or

supersaturated in the beneficial agent. The polymer can be biocompatible, or biodegradable. For purpose of illustration and not limitation, the polymeric material may include, but is not limited to, phosphorylcholine, polycaprolactone, poly-D,L-lactic acid, poly-L-lactic acid, poly(lactideco-glycolide), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(glycolic acid-co-trimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly(amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), polyalkylene oxalates, polyphosphazenes, polyiminocarbonates, and aliphatic polycarbonates, fibrin, fibrinogen, cellulose, starch, collagen, polyurethane including polycarbonate urethanes, polyethylene, polyethylene teraphthalate, ethylene vinyl acetate, ethylene vinyl alcohol, silicone including polysiloxanes and substituted polysiloxanes, polyethylene oxide, polybutylene terephthalate-co-PEG, PCL-co-PEG, PLA-co PEG, polyacrylates, polyvinyl pyrrolidone, polyacrylamide, and combinations thereof. Non-limiting examples of other suitable polymers include thermoplastic elastomers in general, polyolefin elastomers, EPDM rubbers and polyamide elastomers, and biostable plastic material including acrylic polymers, and its derivatives, nylon, polyesters and epoxies. In some embodiments, the stent may include one or more coatings, with materials like poly- D,L lactide (PDLLA). Additionally, some stents may include a coating with materials like the antiproliferative drug everolimus. These materials are merely examples, however, and should not be seen as limiting the scope of the invention.

**[0051]** Some or all of the stent may comprise closed-cell structures formed by intersecting struts. Closed-cell structures may comprise diamond, square, rectangular, parallelogrammatic, triangular, pentagonal, hexagonal, heptagonal, octagonal, clover, lobular, circular, elliptical, and/or ovoid geometries. Closed-cells may also comprise slotted shapes such as H-shaped slots, I-shaped slots, J-shaped slots, and the like. Additionally or alternatively, stent may comprise open cell structures such as spiral structures, serpentine structures, zigzags structures, etc. Strut intersections may form pointed, perpendicular, rounded, bullnosed, flat,

beveled, and/or chamfered cell corners. In an embodiment, stent may comprise multiple different cells having different cell shapes, orientations, and/or sizes.

**[0052]** In general, the embodiments described herein are multi-element, bioresorbable, vascular stents (or “vascular scaffolds”). These stents included multiple stent sections, or “elements,” which are separate from one another but may be referred to together as a multi-element stent. Generally, the stent elements of the multi-element stents described herein will be sufficiently rigid to provide a desired level of strength to withstand the stresses of the vessel in which they are placed, such as a tortuous peripheral vessel. At the same time, a multi element stent will also be flexible, due to the fact that it is made up of multiple separate elements, thus allowing for placement within a curved, torturous blood vessel. Additionally, the multi element stents described herein will usually be balloon-expandable rather than self-expanding, since balloon-expandable stents are typically stronger than self-expanding stents. Each balloon expandable polymeric element of the stent may have relatively high radial force (rigidity) due to the described structures. Elements may have a radial strength significantly higher than self-expanding stents that is similar or greater in magnitude to that of traditional, metal balloon-expandable stents, such as those made of steel or cobalt-chromium.

**[0053]** FIGs. 3A, 3B and 4A-4D illustrate one embodiment of a multi-element stent, as described herein. FIGs. 2A, 2B, 5A-5C, 6A and 6B illustrate longer stent segments. These longer stent segments are provided for exemplary purposes. In some embodiments, a longer stent segment, such as those shown in FIGs. 2A, 2B, 5A-5C, 6A and 6B, may be formed during the manufacturing process and then cut into smaller stent segments/elements to provide a multi-element stent. In other embodiments, a multi-element stent may be made of multiple, longer stent segments, such as those shown in these figures.

**[0054]** As illustrated in FIGs. 2A-6B, in one embodiment, an intravascular stent may include a closed-cell repeating diamond pattern. In alternative embodiments, any other suitable

stent pattern may be used. In this embodiment, the stent may have a strut thickness of about 300-400  $\mu\text{m}$ , although the system can potentially fabricate stents with struts as thin as about 50  $\mu\text{m}$  (current coronary BVSs have a strut thickness of about 158  $\mu\text{m}$ ).

**[0055]** As illustrated in FIGs. 5A-5C, in one embodiment, the stent **10** may have a length of about 22.53 mm, an outer diameter of about 3 mm, an inner diameter of about 2.6 mm, and a wall thickness of about 0.2 mm. These measurements are provided only for exemplary purposes, however. In alternative embodiments, the stent may have any suitable length, diameters and wall thickness. As illustrated in FIG. 5, in one embodiment, the stent may have a diamond or other closed-cell pattern. In this embodiment, the stent comprises intermixed large and small cells. Large cells may be aligned in the longitudinal and/or the circumferential directions in a repeating pattern. Similarly, small cells may be aligned in the longitudinal and/or the circumferential directions in a repeating pattern. Additionally or alternatively, small and large cells may be helically aligned in an alternating pattern. In an embodiment, small cells and large cells are circumferentially offset. Additionally, small cells may be formed at a central location between four adjacent large cells. In an embodiment illustrated in FIG. 5, a first opening dimension **(1)** of a large closed cell is about 0.68 mm, a second opening dimension **(2)** of an adjacent small closed cell is about 0.39 mm, a third dimension **(3)** of a width of a strut between two up-to-down corners of the longitudinally aligned large closed cells is about 0.25 mm, a fourth dimension **(4)** of a width of a strut between two straight portions of the helically aligned large closed cell and small closed cell is about 0.2 mm, and a fifth dimension **(5)** of a width of a strut between two side-to-side corners of the circumferentially aligned large closed cells is about 0.12 mm. Again, these measurements are provided for exemplary purposes only and are not intended to limit the scope of the invention.

**[0056]** In some embodiments, at least one wider strut extends between multiple cells to form a spiral along a length of the stent elements to enhance the radial strength of each of the stent elements. In some embodiments, the wider strut extends from one end to an opposite end of

one of the stent elements. In other embodiments, the wider strut does not extend from one end to an opposite end of one of the stent elements.

**[0057]** FIG. 6A and 6B are side and magnified views, respectively, of the stent **10**, taken via a microscope. The illustrated dimensions are in micrometers and again are provided only as examples.

**[0058]** Referring now to FIGs. 3A-4D, in one embodiment, a multi-element, bioresorbable, vascular stent **20** (or “multi-stent system”) may include multiple stent elements **22**, which in some embodiments may be formed by cutting a longer stent piece, such as that shown in FIGs. 2A, 2B, 5A-5C, 6A and 6B, to form the multiple elements **22**. In an embodiment, multiple stent elements **22** comprise cells having the same cell shapes, orientations, and/or sizes. In another embodiment, multiple stent elements **22** comprise cells having different cell shapes, orientations, and/or sizes. Stent **20** and individual stent elements **22** may have a high radial strength such that stent **20** and individual stent elements **22** are radially rigid and do not exert chronic outward force upon the vessel. Stent **20** and/or individual stent elements **22** may also be flexible along the longitudinal axis of the stent **20**. The stent elements **22** are typically placed in a blood vessel with a certain distance between each adjacent stent element **22**. The multi-element stent **20** may be fabricated on and/or housed on a dowel or other support device. The multi-element stent **20** may be used, for example, to treat long lesions in a blood vessel. In some embodiments, the number of stent elements **22** in the multi-element stent **20** may be selected by a physician user depending on a length of a vascular lesion. In the embodiment shown in FIGs. 3A and 3B, the multi-element stent **20** includes 14 stents, with an interval of about 1 mm between adjacent stent elements **22**. The total length of the multi-element stent **20** is about 66 mm, and a single stent element **22** has a length of about 3.07 mm, inner diameter of about 2.6 mm and outer diameter of about 3 mm. Again, these dimensions are only one example, and any other suitable dimensions may be used in alternative embodiments.

[0059] Referring now to FIGs. 4A-4D, in some embodiments, the stent elements **22** of the multi-element stent **20** may be designed to accommodate a bend around a corner, as illustrated. Some stent elements **22** remain in their straight, unbent configuration, while others conform to a bend. In an alternative embodiment, one stent may be designed to bend around a corner.

[0060] FIGs. 8A-8C illustrate an embodiment of a stent element having a clover or lobular cell configuration. While FIGs. 8A-8C depict cells with four lobes, cells may have any number of lobes. FIG. 8A is a two-dimensional depiction of an element having a lobular cell structure. FIG. 8B is a magnified view of the cells in FIG. 8A. FIG. 8C shows the stent element of FIG. 8A in cylindrical form wherein the two dimensional cells of FIG 8A are wrapped from left to right to form a cylinder. In this embodiment, element **800** comprises intermixed lobular closed cells **801**, **802**. Lobular cells **801** may be aligned in the longitudinal and/or the circumferential directions in a repeating pattern. Similarly, lobular cells **802** may be aligned in the longitudinal and/or the circumferential directions in a repeating pattern. Additionally or alternatively, lobular cells **802** and lobular cells **801** may be helically aligned in an alternating pattern. In an embodiment, lobular cells **802** and lobular cells **801** are circumferentially offset. Additionally, lobular cells **802** may be formed at a central location between four adjacent lobular cells **801**. In an embodiment illustrated in FIGs. 8A-8C, longitudinal lobes **803** aligned longitudinally are larger than circumferential lobes **804** aligned circumferentially. Alternatively, longitudinal lobes **803** may be the same size as circumferential lobes **804**. Longitudinal lobes **803** of adjacent longitudinally aligned lobular cells **801** may be connected by longitudinal connecting struts **805**. Circumferential lobes **804** of adjacent circumferentially aligned lobular cells **801** may be connected by circumferential connecting struts **806**. In an embodiment, longitudinal connecting struts **805** are wider than circumferential connecting struts **806**. Alternatively, longitudinal connecting struts **805** may have the same widths as circumferential connecting struts **806**. Element **800** may take a crimped form when mounted on an unexpanded balloon. Likewise,

element **800** may take an expanded form when expanded by a balloon. Concavities **807** move away from the center of lobular element **800** as the lobular cell **801** moves from a crimped state to an expanded state.

[0061] FIGs. 9A-9B illustrate an alternative embodiment of a stent element having a clover or lobular cell configuration. While FIGs. 9A-9B depict cells with four lobes, cells may have any number of lobes. FIG. 9A is a two-dimensional depiction of an element having this lobular cell structure. FIG. 9B is a magnified view of a cell in FIG. 9A. A stent element with the cell structure of FIG. 9A would have a wrap orientation of left to right to form a cylinder. In this embodiment, element **900** comprises intermixed lobular closed cells **901**, **902**. Lobular cells **901** may be aligned in the longitudinal and/or the circumferential directions in a repeating pattern. Similarly, lobular cells **902** may be aligned in the longitudinal and/or the circumferential directions in a repeating pattern. Additionally or alternatively, lobular cells **902** and lobular cells **901** may be helically aligned in an alternating pattern. In an embodiment, lobular cells **902** and lobular cells **901** are circumferentially offset. Additionally, lobular cells **902** may be formed at a central location between four adjacent lobular cells **901**. In an embodiment, longitudinal lobes **903** aligned longitudinally may be larger than circumferential lobes **904** aligned circumferentially. Alternatively, longitudinal lobes **903** may be the same size as circumferential lobes **904**. Longitudinal lobes **903** of adjacent longitudinally aligned lobular cells **901** may be connected by longitudinal connecting struts **905**. Circumferential lobes **904** of adjacent circumferentially aligned lobular cells **901** may be connected by circumferential connecting struts **906**. In an embodiment, longitudinal connecting struts **905** are wider than circumferential connecting struts **906**. Alternatively, longitudinal connecting struts **905** may have the same widths as circumferential connecting struts **906**. Element **900** may take a crimped form when mounted on an unexpanded balloon. Likewise, element **900** may take an expanded form when expanded by a balloon. Concavities **907** move away from the center of lobular cell **901** as the lobular element **900** moves from a crimped state to an expanded state.

[0062] FIGs. 10A-10F illustrate an embodiment of a stent element having a ratcheting configuration. While FIGs. 10A-10F depict cells with diamond configurations, cells may have any closed cell configuration. FIG. 10A is a two-dimensional depiction of an element having a ratcheting configuration. FIG. 10B is a magnified view of the cells in FIG. 10A. FIG. 10C is an isometric view of the cells in FIG. 10A. FIG. 10D is a cross-sectional view of the cells in FIG. 10C showing the ratchet **1007**. FIG. 10E is a magnified view of a ratchet **1007** in FIG. 10D. FIG. 10F is an alternative view of a ratchet **1007** in cross-section. A stent element with the cell structure of FIG. 10A would have a wrap orientation of left to right to form a cylinder. In this embodiment, element **1000** comprises intermixed ratcheting cells **1001** and non-ratcheting cells **1002**. Ratcheting cells **1001** may be aligned in the longitudinal and/or the circumferential directions in a repeating pattern. Similarly, non-ratcheting cells **1002** may be aligned in the longitudinal and/or the circumferential directions in a repeating pattern. Additionally or alternatively, non-ratcheting cells **1002** and ratcheting cells **1001** may be helically aligned in an alternating pattern. In an embodiment, non-ratcheting **1002** and ratcheting cells **1001** are circumferentially offset. Additionally, non-ratcheting cells **1002** may be formed at a central location between four adjacent ratcheting cells **1001**. In an embodiment illustrated in FIGs. 10A-10F, ratcheting cells **1001** may have the same or similar size as non-ratcheting cells **1002**. Alternatively, ratcheting cells **1001** may be larger or smaller than non-ratcheting cells **1002**. Adjacent longitudinally aligned ratcheting cells **1001** may be connected by longitudinal connecting struts **1005**. Adjacent circumferentially aligned ratcheting cells **1001** may be connected by circumferential connecting struts **1006**. In an embodiment, longitudinal connecting struts **1005** may have larger lengths or widths than circumferential connecting struts **1006**. Alternatively, longitudinal connecting struts **1005** may have the same lengths or widths as circumferential connecting struts **1006**. Ratcheting cells **1001** comprise longitudinally aligned ratcheting struts **1003**. Longitudinally aligned corners of ratcheting cells **1001** and/or longitudinal connecting struts **1005** may comprise cavities **1008** to house linear racks **1009** on ratcheting struts **1003**. Pawl **1010** engages teeth **1011** of linear rack **1009**. Element **1000** may

take a crimped form when mounted on an unexpanded balloon. Likewise, element **1000** may take an expanded form when expanded by a balloon. Linear rack **1007** moves in a longitudinal direction into cavity **1008** (depicted as down to up in FIG. 10E and right to left in FIG. 10F) as the ratcheting element **1000** moves from a crimped state to an expanded state. Ratchet **1007** would thereby increase the radial strength of element **1000**.

**[0063]** FIGs. 11A-11F illustrate an embodiment of a stent element having a bistable spring band configuration. While FIGs. 11A-11F depict cells with diamond configurations, cells may have any closed cell configuration. FIG. 11A is a two-dimensional depiction of an element having a bistable spring band configuration. FIG. 11B is a magnified view of the cells in FIG. 11A. FIG. 11C is an isometric view of the cells in FIG. 11A. FIG. 11D is a cross-sectional view of the cells in FIG. 11C showing the curvature of bistable strut **1103**. FIG. 11E is a magnified view of a bistable strut **1103** in FIG. 11D. FIG. 11F is an alternative view of a bistable strut **1103** in cross-section. A stent element with the cell structure of FIG. 11A would have a wrap orientation of left to right to form a cylinder. In this embodiment, element **1100** comprises intermixed bistable cells **1101** and non-bistable cells **1102**. Bistable cells **1101** may be aligned in the longitudinal and/or the circumferential directions in a repeating pattern. Similarly, non-bistable cells **1102** may be aligned in the longitudinal and/or the circumferential directions in a repeating pattern. Additionally or alternatively, non-bistable cells **1102** and bistable cells **1101** may be helically aligned in an alternating pattern. In an embodiment, non-bistable **1102** and bistable cells **1101** are circumferentially offset. Additionally, non-bistable cells **1102** may be formed at a central location between four adjacent bistable cells **1101**. In an embodiment illustrated in FIGs. 11A-11F, bistable cells **1101** may have the same or similar size as non-bistable cells **1102**. Alternatively, bistable cells **1101** may be larger or smaller than non-bistable cells **1102**. Adjacent longitudinally aligned bistable cells **1101** may be connected by longitudinal connecting struts **1105**. Adjacent circumferentially aligned bistable cells **1101** may be connected by circumferential connecting struts **1106**. In an embodiment, longitudinal connecting struts

**1105** may have larger lengths or widths than circumferential connecting struts **1106**.

Alternatively, longitudinal connecting struts **1105** may have the same lengths or widths as circumferential connecting struts **1106**. Bistable cells **1101** comprise circumferentially aligned bistable struts **1103**. Bistable struts **1103** have a bistable spring band configuration. In an embodiment, bistable struts **1103** have a concavo-convex shape. Bistable struts **1103** may take a straight form or a bent form wherein the bistable strut **1103** bends in the concave direction.

Rigidity of the bistable strut **1103** in the straight form increases radial strength of the element **1100**. As depicted in FIGs. 11C-11F, the concave curve of bistable strut **1103** is oriented in the longitudinal direction and would face a proximal or distal opening of the cylindrical element **1100**. Element **1100** may take a crimped form when mounted on an unexpanded balloon.

Likewise, element **1100** may take an expanded form when expanded by a balloon. Bistable strut **1103** would have a bent configuration in the crimped form. In the expanded state, the bistable strut would have a straight configuration.

**[0064]** FIGs. 12A-12B illustrate an embodiment of a stent element having a pivoting configuration. FIG. 12A is a two-dimensional depiction of an element having a pivoting configuration. FIG. 12B is a magnified view of the cells in FIG. 12A. A stent element with the cell structure of FIG. 12A would have a wrap orientation of left to right to form a cylinder. In this embodiment, element **1200** comprises an alternating sequence of 2 larger cells **1201** and a set of smaller cells **1202**. The two larger cells **1201** allow bending of the free moving pivoting strut **1203** separating the two larger cells **1201**. Element **1200** may take a crimped form when mounted on an unexpanded balloon. Likewise, element **1200** may take an expanded form when expanded by a balloon. FIGs. 12A-12B depict the pivoting strut **1203** in an unstable, less rigid configuration present when the element **1200** is in a crimped state. When expanded, the apex **1204** of the pivoting strut **1203** would shift from the right to the left (based on the orientation in FIG. 12A-12B), thereby increasing the rigidity of the pivoting strut **1203** and increasing the radial strength of the element **1200**.

[0065] FIGs. 13A-13F illustrate an embodiment of a stent element having a corrugated or arch configuration. FIG. 13A is a side view of a cylindrical element having a corrugated configuration. FIG. 13B is a top view of a corrugated element. FIG. 13C is a magnified view of the element in FIG. 13B. FIG. 13D is an isometric view of a cylindrical element having a corrugated configuration. FIG. 13F a magnified view of the element in FIG. 13E. Element **1300** comprises alternating convex ridges **1301** and concave grooves **1302**. In an embodiment, as depicted in FIGs. 13A, 13D, and 13E, element **1300** may comprise solid walls. In an embodiment, corrugated element **1300** may have a longitudinal length of approximately 3mm. Alternatively, corrugated elements may have longitudinal lengths of 1-2mm. Short longitudinal lengths allow stent elements **1300** to be placed with solid walls. In another embodiment, corrugated element **1300** may have cell patterns cut into the corrugated cylinder. Alternatively, element **1300** may be manufactured with arches, ridges, and cell patterns using an additive manufacturing process. Element **1300** may take a crimped form when mounted on an unexpanded balloon. Likewise, element **1300** may take an expanded form when expanded by a balloon. As the corrugated cell **1300** moves from a crimped state to an expanded state, ridges **1301** and/or valleys **1302** will widen.

[0066] Any suitable therapeutic agent (or “drug”) may be incorporated into, coated on, or otherwise attached to the stent, in various embodiments. Examples of such therapeutic agents include, but are not limited to, anti-thrombotics, anticoagulants, antiplatelet agents, anti-lipid agents, thrombolytics, anti-proliferatives, anti-inflammatories, agents that inhibit hyperplasia, smooth muscle cell inhibitors, antibiotics, growth factor inhibitors, cell adhesion inhibitors, cell adhesion promoters, anti-mitotics, anti-fibrins, antioxidants, anti-neoplastics, agents that promote endothelial cell recovery, matrix metalloproteinase inhibitors, anti-metabolites, anti-allergic substances, viral vectors, nucleic acids, monoclonal antibodies, inhibitors of tyrosine kinase antisense compounds, oligo-nucleotides, cell permeation enhancers, hypoglycemic agents, hypolipidemic agents, proteins, nucleic acids, agents useful for erythropoiesis stimulation,

angiogenesis agents, anti-ulcer/anti-reflux agents, and anti-nauseants/anti-emetics, PPAR alpha agonists, sodium heparin, LMW heparins, heparoids, hirudin, argatroban, forskolin, vapriprost, prostacyclin and prostacylin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic anti-thrombin), glycoprotein IIb/IIIa (platelet membrane receptor antagonist antibody), recombinant hirudin, thrombin inhibitors, indomethacin, phenyl salicylate, beta-estradiol, vinblastine, ABT-627 (astrasentan), testosterone, progesterone, paclitaxel, methotrexate, fotemusine, RPR-101511A, cyclosporine A, vincristine, carvediol, vindesine, dipyridamole, methotrexate, folic acid, thrombospondin mimetics, estradiol, dexamethasone, metrizamide, iopamidol, iohexol, iopromide, iobitridol, iomeprol, iopentol, ioversol, ioxilan, iodixanol, and iotrolan.

**[0067]** Examples of anti-thrombotics, anticoagulants, antiplatelet agents, and thrombolytics include, but are not limited to, sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapriprost, prostacyclin and prostacylin analogues, dextran, Dphe- pro-arg-chloromethylketone (synthetic anti-thrombin), dipyridamole, glycoprotein IIb/IIIa (platelet membrane receptor antagonist antibody), recombinant hirudin, thrombin inhibitors, and thrombolytic agents.

**[0068]** Examples of cytostatic or anti-proliferative agents include, but are not limited to, rapamycin and its analogs, including everolimus, zotarolimus, tacrolimus and pimecrolimus, angiopeptin, angiotensin converting enzyme inhibitors, such as captopril, cilazapril or lisinopril, calcium channel blockers, such as nifedipine, amlodipine, cilnidipine, lercanidipine, benidipine, trifluperazine, diltiazem and verapamil, fibroblast growth factor antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin, topoisomerase inhibitors, such as etoposide and topotecan, as well as antiestrogens such as tamoxifen.

**[0069]** Examples of anti-inflammatory agents include, but are not limited to, colchicine and glucocorticoids, such as betamethasone, cortisone, dexamethasone, budesonide,

prednisolone, methylprednisolone and hydrocortisone. Non-steroidal anti-inflammatory agents include, but are not limited to, flurbiprofen, ibuprofen, ketoprofen, fenoprofen, naproxen, diclofenac, diflunisal, acetominophen, indomethacin, sulindac, etodolac, diclofenac, ketorolac, meclofenamic acid, piroxicam and phenylbutazone.

**[0070]** Examples of anti-neoplastic agents include, but are not limited to, alkylating agents including altretamine, bendamucine, carboplatin, carmustine, cisplatin, cyclophosphamide, fotemustine, ifosfamide, lomustine, nimustine, prednimustine, and treosulfan, antimitotics, including vincristine, vinblastine, paclitaxel, docetaxel, antimetabolites including methotrexate, mercaptopurine, pentostatin, trimetrexate, gemcitabine, azathioprine, and fluorouracil, and antibiotics, such as doxorubicin hydrochloride and mitomycin. Antiallergic agents include, but are not limited to, permirolast potassium nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine, and nitric oxide.

**[0071]** Although particular embodiments have been shown and described, they are not intended to limit the invention. Various changes and modifications may be made to any of the embodiments, without departing from the spirit and scope of the invention. The invention is intended to cover alternatives, modifications, and equivalents.

WHAT IS CLAIMED IS:

1. A device for placement within a blood vessel to maintain or enhance blood flow through the blood vessel, the device comprising multiple, balloon-expandable, bioresorbable, vascular stent elements configured to be implanted in the blood vessel as a multi-element stent, with the multiple stent elements not touching one another;

wherein the stent elements comprise a first set of closed cells and a second set of closed cells, wherein the first set of closed cells have a different shape or size than the second set of closed cells;

wherein the first set of closed cells have a repeating longitudinally aligned pattern and a repeating circumferentially aligned pattern, wherein the second set of closed cells have a repeating longitudinally aligned pattern and a repeating circumferentially aligned pattern, wherein the first set of closed cells and the second set of closed cells are circumferentially offset, and wherein the first set of closed cells and the second set of closed cells have a helically aligned alternating pattern.

2. The device of claim 1, wherein the first set of closed cells are larger cells having a first opening dimension and the second set of closed cells are smaller cells having a second opening dimension smaller than the first opening dimension;

wherein each of the larger closed cells is formed by at least one wider strut and at least one thinner strut, wherein the wider strut has a first width and the thinner strut has a second width less than the first width; and

wherein the wider struts are between adjacent longitudinally aligned larger closed cells, and wherein the thinner struts are between adjacent circumferentially aligned larger closed cells.

3. The device of claim 2, wherein each of the larger closed cells is further formed by at least one intermediate-width strut, wherein the intermediate-width strut has a third width smaller than the first width and larger than the second width; and

wherein the intermediate-width struts are between adjacent helically aligned larger closed cells and smaller closed cells.

4. The device of claim 1, wherein first set of closed cells have a first lobular shape and the second set of closed cells have a second lobular shape.

5. The device of claim 4, wherein each of the cells of the first set of closed cells comprise longitudinally aligned lobes and circumferentially aligned lobes; wherein the longitudinally aligned lobes are larger than the circumferentially aligned lobes.

6. The device of claim 5, wherein adjacent longitudinally aligned lobes are connected by longitudinal connecting struts and adjacent circumferentially aligned lobes are connected by circumferential connecting struts.

7. The device of claim 1, wherein the first set of closed cells are ratcheting cells and the second set of closed cells are non-ratcheting cells.

8. The device of claim 7, wherein each of the ratcheting cells comprise a longitudinally aligned ratcheting strut; wherein teeth on a portion of the ratcheting strut are configured to move within a cavity and engage a pawl.

9. The device of claim 1, wherein the first set of closed cells are bistable cells and the second set of closed cells are non-bistable cells, wherein the bistable cells comprise a circumferentially aligned bistable strut having a bistable spring band configuration.

10. The device of claim 9, wherein the bistable struts have a concavo-convex shape with the concave curve longitudinally oriented.

11. A device for placement within a blood vessel to maintain or enhance blood flow through the blood vessel, the device comprising multiple, balloon-expandable, bioreversible, vascular stent elements configured to be implanted in the blood vessel as a multi-element stent, with the multiple stent elements not touching one another;

wherein the stent elements have a corrugated cylindrical configuration with alternating convex ridges and concave grooves.

12. The device of claim 11, wherein the stent elements have solid walls.

13. The device of claim 11, wherein the stent elements have non-solid walls with cell patterns.

14. A device for placement within a blood vessel to maintain or enhance blood flow through the blood vessel, the device comprising multiple, balloon-expandable, bioresorbable, vascular stent elements configured to be implanted in the blood vessel as a multi-element stent, with the multiple stent elements not touching one another;

wherein the stent elements comprise an alternating sequence of two larger cells and a set of smaller cells; wherein the two larger cells are formed by a pivoting strut between the two larger cells.

15. The device of claim 14, wherein the pivoting strut is configured to pivot from a less rigid state to a more rigid state.

16. A method of making a multi-element, bioresorbable, vascular stent, the method comprising:

forming a length of the bioresorbable, vascular stent from a bioresorbable material that is balloon expandable and not self-expanding using an additive manufacturing process, wherein the stent elements comprise a first set of closed cells and a second set of closed cells having a different shape or size than the first set of closed cells, wherein the first set of closed cells have a repeating longitudinally aligned pattern and a repeating circumferentially aligned pattern, wherein the second set of closed cells have a repeating longitudinally aligned pattern and a repeating circumferentially aligned pattern, wherein the first set of closed cells and the second set of closed cells are circumferentially offset, and wherein the first set of closed cells and the second set of closed cells have a helically aligned alternating pattern; and

cutting the length of the bioresorbable, vascular stent to form multiple stent elements of the stent.

17. The method of claim 16, wherein the additive manufacturing process comprises micro-stereolithography.

18. The method of claim 16, wherein the additive manufacturing process comprises 3D printing.

19. The method of claim 16, wherein the bioresorbable material is selected from the group consisting of poly(L-lactic acid) (PLLA), polyglycolic acid (PGA), and poly(iodinated desaminotyrosyl-tyrosine ethyl ester) carbonate.

20. The method of claim 19, further comprising applying a coating to the bioresorbable material.

21. The method of claim 20, wherein the coating comprises poly-D,L-lactide (PDLLA).

22. The method of claim 16, further comprising applying a drug to the stent.

23. The method of claim 22, wherein the drug is selected from the group consisting of everolimus and other anti-proliferative drugs.

24. A method for maintaining or enhancing blood flow through a blood vessel, the method comprising:

advancing a balloon catheter into the blood vessel;

expanding a balloon on the balloon catheter to expand multiple, bioresorbable, vascular stent elements disposed on the balloon to contact an inner wall of the blood vessel, wherein the stent elements comprise a first set of closed cells and a second set of closed cells having a different shape or size than the first set of closed cells, wherein the first set of closed cells have a

repeating longitudinally aligned pattern and a repeating circumferentially aligned pattern, wherein the second set of closed cells have a repeating longitudinally aligned pattern and a repeating circumferentially aligned pattern, wherein the first set of closed cells and the second set of closed cells are circumferentially offset, and wherein the first set of closed cells and the second set of closed cells have a helically aligned alternating pattern;




deflating the balloon, while leaving the vascular stent elements in place in the blood vessel; and

removing the balloon catheter from the blood vessel.

25. The method of claim 24, wherein the blood vessel comprises a peripheral blood vessel.

26. The method of claim 24, wherein expanding the stent elements comprises expanding at least four stent elements.

27. The method of claim 24, wherein the stent elements are separated from one another along the balloon, and wherein expanding the stent elements comprises delivering the stent elements to the inner wall of the blood vessel in a spaced-apart configuration.






FIG. 3A




FIG. 3B




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4D




FIG. 5A

FIG. 5B




FIG. 5C




FIG. 6A




FIG. 6B




FIG. 7




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 9A




FIG. 9B

10/23




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D




FIG. 10E




FIG. 10F




FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D




FIG. 11E




FIG. 11F




FIG. 12A




FIG. 12B




FIG. 13A

21/23




FIG. 13B




FIG. 13C




FIG. 13D




FIG. 13E

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 2016/020743

## A. CLASSIFICATION OF SUBJECT MATTER

**A61F 2/90 (2013.01)****A61F 2/958 (2013.01)**

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61F 2/01, 2/06, 2/82, 2/90, 2/958

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PatSearch (RUPTO internal), DWPI, Espacenet, Google, Rambler, Yandex

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2014/091438 A2 (SHALYA MEDICAL TECHNOLOGIES (INDIA) PVT. LTD) 19.06.2014, abstract, claims 1, 2, 3, 25, p. 3, lines 8-31, p. 5, lines 2-7, 17-27, p. 6, lines 12-14, p. 14, lines 4-7, p. 21, lines 2-32, p. 22, lines 26-30, p. 23, lines 4-30, p. 25, lines 23-32, p. 27, lines 1-3, p. 36, lines 23-25, p. 38, lines 7-8, fig. 16e, 25	16-23
Y		1-15, 24-27
Y	US 7481837 B2 (ADVANCED CARDIOVASCULAR SYSTEMS, INC.) 27.01.2009, abstract, claim 1, col. 5, lines 63-67, col. 6, lines 1-17, col. 8, lines 35-40, fig. 1-4	1-15, 24-27
Y	WO 2003/022178 A1 (CATHNET-SCIENCE HOLDING A/S et al.) 20.03.2003, abstract, p. 10, lines 8-20, p. 12, lines 19-30, p. 13, lines 4-25, p. 14, lines 15-31, p. 15, lines 3-16, p. 17, lines 4-29, fig. 1-3, 4A, 8, 10, 11, 21-24	2-13, 15



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document but published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

23 May 2016 (23.05.2016)

Date of mailing of the international search report

30 June 2016 (30.06.2016)

Name and mailing address of the ISA/RU:

Federal Institute of Industrial Property,  
Berezhkovskaya nab., 30-1, Moscow, G-59,  
GSP-3, Russia, 125993

Facsimile No: (8-495) 531-63-18, (8-499) 243-33-37

Authorized officer

E. Nosova

Telephone No. (495)531-64-81